IMGN — ImmunoGen Cashflow Statement
0.000.00%
Last trade - 00:00- $8.72bn
- $8.22bn
- $108.78m
- 34
- 12
- 95
- 44
Annual cashflow statement for ImmunoGen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -169 | -104 | -44.4 | -139 | -223 |
| Depreciation | |||||
| Non-Cash Items | -4.7 | -14 | -31.8 | -8.58 | 16.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.294 | 25.7 | -4.56 | -23.6 | -25.6 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -166 | -88.4 | -78.6 | -169 | -230 |
| Capital Expenditures | -5.25 | -2.85 | -0.917 | -1.43 | -1.36 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | 2.31 | 1.43 | — | — |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -5.25 | -0.533 | 0.509 | -1.43 | -1.36 |
| Financing Cash Flow Items | 0 | 0 | — | 199 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 167 | 2.87 | 196 | 356 | 27.6 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -4.86 | -86 | 118 | 185 | -204 |